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Abstract
Background: Patient recruitment can be very challenging in paediatric studies, especially in relatively uncommon
conditions, such as juvenile idiopathic arthritis (JIA). However, involving children and young people (CYP) in the
design of such trials could promise a more rapid trajectory towards making evidence-based treatments available.
Studies involving CYP are advocated in the literature but we are not aware of any early stage feasibility studies that
have qualitatively accessed the perspectives of parents and CYP with a long term condition to inform design and
conduct of a trial. In the context of a feasibility study to inform the design of a proposed randomised controlled
trial of corticosteroid induction regimen in JIA, we explored families’ perspectives on the proposed trial and on JIA
trials generally.
Methods: We analysed interviews with 27 participants (8 CYP aged 8–16 years and 19 parents) from four UK
paediatric rheumatology centres. CYP had recently received corticosteroids to treat JIA. Audio-recorded interviews
were transcribed and analysed thematically, drawing on the Framework Method.
Results: Both parents and CYP were capable of engaging with the logic of the proposed trial but pointed to
challenges with its design. Treatment preferences influenced willingness to participate in the proposed trial. The
preferences of older children and their parents often differed, with CYP being more willing to participate in the
proposed trial than parents. Families’ current treatment preferences were largely informed by past positive and
negative treatment experiences. Some participants also indicated that their treatment preferences were influenced
by those of their clinicians.
Conclusion: Previous research has typically focused on deficits in patients’ understandings of trials. We found that
both parents and CYP understood trial concepts and were able to identify potential flaws in the proposed trial. We
propose recommendations to optimise the design of a planned corticosteroid induction regimen trial in JIA.
Accessing both parents’ and CYP’s perspectives helps to identify and address recruitment challenges, which will
ultimately optimise informed consent and future recruitment.
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Introduction
Juvenile idiopathic arthritis (JIA) refers to a collection of
inflammatory arthritides (commonly divided into several
subtypes) with symptom onset at, or before the age of
16 years [1]. There has been a recent increase in the
number of JIA randomised controlled trials [2]. Recruit-
ment is crucial to the success of such trials, and poor
recruitment can inflate costs [3], result in underpowered
trials, and lead to potentially effective interventions
being abandoned or delayed [4]. Approximately 45% of
UK multi-centre trials do not achieve their original re-
cruitment target, often resulting in costly recruitment
extensions [5].
Patient recruitment can be especially challenging in
paediatric studies, and in relatively uncommon condi-
tions, such as JIA [6, 7]. Compared with trials in adult
rheumatology, consent seeking can be more complex
due to the need to involve both child and parents in
enrolment decisions [8], and some drug treatments
may be poorly tolerated by younger children [9]. In-
novative trial methodology and involving parents and
children and young people (CYP) in the design of JIA
trials promises a more rapid trajectory towards
making evidence-based treatments available to young
patients [10, 11].
Increasingly, researchers are using qualitative
methods to explore patients’ views of trial feasibility,
and to proactively identify and address problems that
may otherwise undermine a trial [12, 13]. Early stage
feasibility studies, without a randomised component,
are a distinct subtype of feasibility study. These are
often used to resolve fundamental questions, such as
which treatments to compare, or uncertainties about
the ‘in principle’ acceptability of a trial to patients
and recruiters before committing resources to a pilot
or full randomised trial.
Although studies involving CYP are advocated in the
literature [14, 15], we are aware of only one early stage
feasibility study that has qualitatively investigated per-
spectives of both parents and CYP to inform the design
and conduct of a trial [14]. This recent study focused on
the experiences of CYP with acute osteomyelitis or
septic arthritis, whereas the current study explored the
perspectives of CYP with JIA. JIA is a long term condi-
tion, CYP with JIA may find the prospect of trial partici-
pation especially challenging due to preferences arising
from their ongoing experiences of the condition and dif-
ferent treatments [15]. Research is needed to shed light
on such issues. This article explores what an early phase
qualitative feasibility study, involving interviews with
both parents and CYP, can tell us about the viability of a
proposed JIA trial of corticosteroid induction regimens.
We also report on the wider barriers and opportunities
for recruitment in JIA trials.
Methods
We adopted a qualitative approach involving
semi-structured interviews. Qualitative research provides
in-depth insights on participants’ experiences and
perspectives. Such studies are typically characterised by
smaller sample sizes but rich, voluminous data [16].
Qualitative research has been used to identify and
address key uncertainties in planning and designing
proposed trials for adult patients [12]. Semi-structured
interviews are a qualitative research method well suited
to exploring the perceptions of patients regarding
complex and sensitive issues [17], as these enable
families to raise matters of importance to them, and for
interviewers to inform families about trials and clarify
any misunderstandings.
A Research Ethics Committee in the North East of
England (The North East – Newcastle and North
Tyneside 2) approved this study (16/NE/0047).
Participant selection
Within four UK paediatric and adolescent rheumatology
centres, clinicians approached families of children and
young people who met the eligibility criteria (Table 1),
briefly described the study and requested verbal permis-
sion for a researcher to contact families. Children and
young people had a confirmed diagnosis of JIA in line
with current guidance [1, 18]. FS and LR, both experi-
enced in qualitative research in health settings, con-
ducted the interviews after seeking informed consent
from parents and assent or consent from CYPs. Inter-
views took place from August 2016 to March 2017 and
were audio recorded and transcribed. The research team
monitored sampling characteristics to ensure these were
inclusive of patients of varying ages, and of families from
a range of treatment centres and socioeconomic back-
grounds. Sampling for interviews ceased when data
saturation was reached, that is, when further interviews
were no longer contributing new information [19].
Interview protocol
Semi-structured, topic-guided interviews (Additional file 1:
Appendix A) were conversational to allow participants to
raise and reflect on matters of concern to them. While we
interviewed all parents regardless of their child’s age,
only children aged eight years and over were
interviewed. We developed separate topic guides for
Table 1 Inclusion criteria for qualitative interviews with families
Inclusion criteria
• CYP≤ 16 years.
• CYP has received a clinical diagnosis of JIA.
• CYP has recent experience (≤ 12 months) of at least one of four
corticosteroid delivery routes: (a) oral prednisolone (tablets); (b)
intravenous methylprednisolone (IV); (c) intra-articular injection(s)
(IACI), or; (d) intra-muscular injection (IM).
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parents, children (8–12 years), and young people (13–
16 years), and adapted these throughout the study,
guided by the ongoing analysis. We also developed
stimulus materials to facilitate the interviews, includ-
ing a video, a flow chart illustrating the proposed
trial, and prompt cards detailing potential benefits
and side effects of the four corticosteroid delivery
routes (Additional file 2: Appendix B). Consultant
paediatric rheumatologists advised on the develop-
ment of the prompt cards. These cards listed key
points about the delivery routes that the rheumatolo-
gists perceived relevant to patients and families. The
cards were intended to facilitate discussion in the in-
terviews, rather than to provide an exhaustive list of
benefits and side effects of the delivery routes.
In brief, the proposed trial was described to partici-
pants as comparing four corticosteroid delivery routes
(hereon referred to as treatments): (a) oral prednisolone
(referred to herein as tablets); (b) intravenous methyl-
prednisolone (IV); (c) intra-articular injection(s) (IACI),
and; (d) intra-muscular injection (IM). These four
treatments are widely used in clinical practice for JIA,
although the only informative evidence-base of effective-
ness and efficacy is for IACI [20, 21]. Referring to the
prompt cards the interviewer described the four delivery
routes to families, including the process of delivery (e.g.
duration) and potential pros and cons. While a trial
could help to establish which of the treatments is most
effective in treating JIA, the feasibility of such a trial is
uncertain.
Qualitative analysis
We drew on The Framework Method [16], an approach
to the thematic analysis of qualitative of data [22], and
used NVivo 10 to assist with data indexing and coding
[23]. FS, LR and BY initially read a selection of
transcripts and discussed the developing analysis. FS and
LR double-coded approximately 10% of transcripts,
discussing divergences and their resolution, leading to
the development of a preliminary coding framework.
Remaining transcripts were coded by either FS or LR
and further analysis meetings were organised involving
the research team (BY, LR, and FS) throughout the
course of analysis to discuss convergences and diver-
gences, identify quotes for report writing, and review
data saturation.
In quantitative research, numbers contribute to the
persuasive “power” of the findings, whereas, in qualita-
tive research, the words of participants enable the reader
to judge whether the research team’s interpretations of
the data are grounded in the experience of the partici-
pants [24]. The research team selected participant
quotes for this report to illuminate and explicate the re-
searchers’ synopsis of the themes identified through
systematic data analysis [25, 26]. A draft report of the
analysis containing extensive data extracts was circulated
to the wider study team. This enabled investigator
triangulation helping to ‘test’ and refine the analysis.
Participants were sent a summary of the study findings.
Results
Participants
All 26 eligible families identified by clinicians agreed to
researcher contact. Of these, nine could not be
contacted and two declined. Twenty-eight participants
from 15 families completed or attempted an interview
(58% response rate), comprising nine patients and 19
parents (Table 2). In one of the 28 interviews, we were
unable to sufficiently engage the patient (C8) in discuss-
ing the concepts that we wished to explore. As no mean-
ingful data were obtained this patient’s interview was
not transcribed or analysed, although his parents’
interview was. Another patient’s interview (C11) was un-
usually short (six minutes) as the family had limited time
but her parent was interviewed and child and parent in-
terviews were analysed. Excluding the outlier interview
(C11), interviews lasted from 23 to 76 min (Median = 43
[IQR = 35–54] minutes).
Participants were interviewed in their homes (n = 9),
in a private setting in the paediatric rheumatology clinic
(n = 4), in a parent’s workplace (n = 1) or by telephone
(n = 1). Of the nine CYP, two were interviewed jointly
with their parents, while seven were interviewed separ-
ately. Of 19 parents, 14 were interviewed separately
while five were interviewed with their child present, in-
cluding the two noted above, and three parents whose
children were ≤ 7 years and ineligible for interview.
As Table 2 shows, CYP’s ages ranged from 1 to 16
years, and most were female (n = 9/16, 56%). One family
had two CYP with JIA. All but two families (n = 13/15)
had experienced at least two treatments, and most CYP
had established JIA with a recent disease flare (n = 10/16).
IACI was the most common treatment experienced
(n = 14/16). While the inclusion criteria stated that
patients needed to have had corticosteroids within the
past 12 months (see Table 1), all families reported that
patients were treated within the past 6 months and al-
most a third (n = 4/15) were actively receiving at least
one corticosteroid treatment at the time of interview.
We obtained families’ postcodes wherever possible and
used the Indices of Multiple Deprivation (IMD), a meas-
ure of socio-economic status, to inform sampling and en-
sure representation from all socio-economic groups: 6/13
(46%) families lived in areas of high deprivation (IMD de-
cile 1–3), 5/13 (38%) in areas of moderate deprivation
(IMD decile 4–6), and 2/13 (15%) in the least deprived
(IMD decile 7–10) areas of England [27].
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Willingness to participate: Protective parents and
permissive children
Participant is indicated (Mo =mother, Fa = father, or C =
child) with family number (see Table 2 for family num-
ber reference). Patients’ age categories are provided (e.g.
14-16y). Ellipsis (...) indicate omitted text and square
brackets indicate explanatory text.
Families recognised the need for JIA trials and some
expressed enthusiasm for the proposed trial: “I would
[participate] ‘cause I’ve always been up for like helping
with research (Mo2_5-7y)”; “It is a very good topic to
actually do a research on […] it’s one that’s needed
because there are many ways of [delivering] steroids”
(C3_14-16y). CYP often suggested that participation in
the proposed trial could be of benefit to either
themselves or others: “I’d try it [the trial], yeah… It
seems fine… If it’s going to help, it’s going to help”
(C14_14-16y).
How CYP and parents perceived randomisation influ-
enced their views of the trial. For the most part, both
parties appeared to grasp the rationale for randomisation
as a means to avoid bias: “I do think it will be best if it’s
chosen by a computer because some patients might be
biased.” (C3_14-16y). However, at times some parents
struggled to reconcile randomisation with a need to trust
in clinicians’ expertise: “I’d go with just whatever’s the
best one and that’s why, that’s why I’m trusting [the
doctors] to get her better… I wouldn’t be comfortable with
the computer randomly selecting what would be the best
course of treatment for her.” (Fa15_14-16y).
Others struggled to reconcile randomisation with their
need as parents to have confidence in the care being
provided for their child: “We were told the steroid injec-
tions would help her, so that sort of put confidence in us.
But for someone to say we’re not quite sure which one the
best one is, so we’re going to do it randomly, I think that
would put a lot of sort of discomfort in us.” (Mo7_1-4y).
In contrast, only one young person was opposed to par-
ticipating in the proposed trial, rejecting randomisation
in favour of a clinician-informed treatment: “I would
have said no because... the doctor needs to tell you what’s
best for you and not a computer because a computer
doesn’t know that.” (C12_11-13y).
The comments of other CYP indicated they were open
to participating and some expressed a degree of noncha-
lance to their treatment being randomised as part of
research participation: “I’d be like ‘It’s been happening for
this long, I don’t care anymore, you can do whatever, do
anything with my body, it’s alright!’” (C13_14-16y). In
some of the joint interviews, CYP were more permissive
about research than their parents and suggested that
they would be more willing to participate in such a trial:
C13: [At diagnosis] I haven’t experienced any of them
[treatments] so far so it wouldn’t hurt to try any of
them…
Table 2 Characteristics of participants in the study
Family
number
Parent
interviewed
Child/young
person’s age
Child/young person’s JIA
status (reported by clinician)
Treatments experienced by the child/young personb
Tablets IV IM IACI
1 a Mo, Fa 11–13 Flare ✓ ✓ ✓ ✓
2 Mo 5–7 Flare ✓ ✓
3 a Mo 14–16 Flare ✓ ✓ ✓
4c Mo, Fa 1–4, 5–7 Diagnosis, Flare ✓ ✓
5 Mo 1–4 Diagnosis ✓
6 Mo 5–7 Diagnosis ✓ ✓
7 Mo, Fa 1–4 Diagnosis ✓
8 a Mo, Fa 8–10 Flare ✓ ✓
9 a Mo 11–13 Diagnosis ✓ ✓
10 a Mo 14–16 Flare ✓ ✓ ✓ ✓
11 a Mo 8–10 Flare ✓ ✓
12 a Mo 11–13 Diagnosis ✓ ✓
13 a Mo 14–16 Flare ✓ ✓
14 a Mo 14–16 Flare ✓ ✓
15 Fa 14–16 Flare ✓ ✓
Mo =Mother, Fa = Father, Tablets = Oral prednisolone, IV = Intravenous methylprednisolone, IM = Intra-muscular injection, IACI = Intra-articular injection(s). JIA status
as reported by clinician
aFamilies where the child/young person was also interviewed, bReported by parents, cFamily with two children with JIA
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Mo13: I think I might have been a little bit more
concerned ‘cause I think I would want, at the beginning
when we didn’t know a lot about it, I think I would
have been thinking, oh no, I need to have the consultant
say what’s best for him. (14-16y)
This permissive attitude among CYP may have been
founded in part on feeling confident that clinicians
would always prioritise their care over the trial: “I’d
probably take part in it just to like help the research
and, ‘cause I think if something didn’t work on me I know
that… they’d just put me on something else like in the
end.” (C9_11-13y).
Barriers and facilitators to participation
Our analysis identified several potential recruitment bar-
riers and facilitators to the proposed trial, some of which
were voiced by parents but not CYP and vice versa. For
example, some parents questioned or remarked on the
number of visits to clinic that the proposed trial would
entail, noting that it was already challenging to attend
clinic appointments due to work or school commit-
ments. Parents thereby implied that their willingness to
participate would hinge on the convenience or otherwise
of the trial: “Would that entail, mean more hospital
visits though, to do this trial? ‘Cause obviously with work
we’d be struggling, it depends how often that would be.”
(Mo2_5-7y). Some CYP acknowledged these factors but
did not suggest that this would be a barrier to participa-
tion: “Mam doesn’t really mind going to the hospital and
that, because obviously she does it because it helps me.”
(C14_14-16y).
Past treatment experiences
Families spoke of their experience of different treatments
over numerous disease flares since diagnosis. This ex-
perience heavily influenced their views on the proposed
trial and their willingness to participate. Reflecting on a
treatment that “had worked”, one mother indicated that
she would like her child to receive the same treatment if
they experienced a future flare-up: “When you’re first di-
agnosed you will try any of the medication, but now we
know what works for [my child] I would want to stick
with that.” (Mo14_14-16y). Conversely, on realising that
joining the trial could mean her child receiving a treat-
ment that had previously “not worked”, another mother
questioned the logic of offering the same treatment in
the context of a trial: “If it’s not worked this time, what
makes them think it’s going to work the second time?”
(Mo6_5-7y). That is, parents struggled to see the logic
behind randomising a child to a treatment that they had
previously experienced as ineffective, and this was an
important issue they would want clinicians to address
should such a trial be offered to them.
Older children and their parents frequently differed in
their treatment preferences, with both parties often not-
ing drawbacks of treatments that the other had not
identified:
C12: I’d rather [have IV].
Mo12: You’d rather have [IV] than just have a needle in
your bum? I think I’d rather have the needle in
my bum than be sat here.
C12: Wouldn’t [IM] hurt? That would hurt more
surely?
Mo12: … well you’ve had to come here for three days
[for IV].
C12: It doesn’t bother me. It’s like an hour on this and
then it’s done. (11-13y)
Mo13: … to me, [IM] would be a lot less painful going
in your butt ‘cause you’ve got that little
meatiness, do you know, something to put it in.
C13: Any muscle anywhere else I probably would have
been fine. Like you could just stick it in my thigh
or something that’s okay but I don’t want to have
to get the moon out for you. (14-16y)
Some CYP were receiving corticosteroids at the time
they were interviewed. Despite being unable to assess
the effect of the current treatment in reducing symp-
toms at that point in time, one young person explained
that he preferred his current treatment over other
treatments, even ones he had not been prescribed: “I’d
say [I prefer] this one… because my experience right
now… I feel quite, quite fine on this. Probably [would
then have] tablets since I haven’t experienced those
[tablets]” (C13_14-16y), implying that treatment side ef-
fects also weighed heavily in his treatment preferences.
CYP with multiple affected joints often received corti-
costeroids via several delivery routes, either simultan-
eously or consecutively, which made it difficult for them
and their parents to differentiate the effect of an individ-
ual treatment: “I don’t know [which is best] because like I
feel like the intravenous and the tablets go along with
each other in a way because I’m on both at the minute.”
(C12_11-13y). Most families also had experience of
non-corticosteroid treatments for JIA, such as other
immunosuppressive medication, hydrotherapy, or
physiotherapy, and some were concerned about the
possibility that interactions between corticosteroid and
non-corticosteroid treatments could jeopardise the valid-
ity of the proposed trial’s findings if non-corticosteroid
treatment effects were not controlled for: “The challenge
is that they don’t have this treatment independently of
other things, do they? It’s always combined with
something else or it has been in our experience. So, it’ll
be steroids plus something else.” (Mo10 14-16y). Some
parents also queried whether they could continue with
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existing treatments if their child was to participate in a
trial of corticosteroids: “I don’t know, would they stop
the methotrexate or would they just carry it on?” (Mo4
1-4y, 5-7y). These illustrate further issues that clinicians
would need to address when inviting families to take
part in JIA trials.
Perceived treatment suitability
While families did not view any one of the four delivery
routes as unsuitable overall to be evaluated in the
proposed trial, they did perceive certain treatments as
more or less acceptable for certain CYP. Families held
these views even when they did not have direct experi-
ence of the treatment concerned. Parents believed that
treatment suitability depended on a child’s age. For
example, a mother anticipated that her eight-year-old
would not tolerate IV: “He’s not going to want to stand
there for hours… I would imagine if he got lots and lots
of flare-ups, and he is older and he understands it, I can
see the logic behind that.” (Mo11 8-10y). While a child’s
age seemed important to parents in making decisions
about treatments, and therefore in designing the trial,
CYP did not comment on this.
Both parents and CYP believed that treatments varied
in their suitability for different patient groups or JIA
subtypes. For example, one child suggested that IV is
more suitable when a child has more than one joint
affected: “If you have a flare and it doesn’t just affect one
joint, then [IV], it’d kind of help you more.” (C9_
11-13y). Similarly, a mother of a child with localised JIA
echoed the view that treatments varied in their suitabil-
ity for different JIA subtypes and implied that IV could
also be potentially harmful for her child due to its sys-
temic nature: “The intravenous one would affect the
whole body, so I don’t know whether that would be a
good thing or not. I’ve never experienced that, we’ve only
ever had the joint injections.” (Mo2 5-7y). Parents and
some children therefore struggled to see the logic of a
trial in which they might receive a treatment, that, based
on their knowledge of JIA and how treatments worked,
was ill suited to their subtype of JIA.
Being approached about research at diagnosis
Given the powerful influence of past treatment experi-
ences on current treatment preferences, it was unsur-
prising that most participants were more comfortable
with the idea of participating in the trial if invited at
diagnosis when treatments would be new to families:
“[We would participate] at the beginning when he had it,
probably it will be different but now, no way… we had
such a big, big problems with his injection…” (Mo8_
8-10y). Nevertheless, there were some exceptions. Sev-
eral parents recalled the emotional upheaval of learning
that their child had a life changing condition and their
strong desire for certainty at that time. One mother
explained that if she was asked to enter her child into a
trial in the aftermath of diagnosis: “I’d probably say
‘Not yet’” (Mo9_ 11-13y).
CYP did not view trial recruitment at diagnosis to be
problematic, again pointing to divergence in the views of
the two parties. Overall, parents often described their
children as resilient and CYP themselves rarely de-
scribed the emotional upheaval of receiving a diagnosis
but they did reflect on how the diagnosis had affected
their parents:
I: What was it like being told about having arthritis?
C9: I don’t know, I think I took it a bit better than my
mum, ‘cause mums are mums, so they get a bit worried.
(11-13y)
Families’ accounts of clinicians’ treatment preferences
Both parents and CYP referred to the relationships they
had with their clinician and how they trusted them to
accurately inform them about treatments and provide
them with optimal care: “The doctors have been so
good… I’ve got to trust what they are telling me and what
they think is best” (Fa15_ 14-16y).
I: Who do you think would be the best person to give
you more information about the research study?
C1: Probably doctors and that so you know it’s true, in
case like random people just say this works. (11-13y)
Families spoke about treatment preferences that their
clinician had voiced when making recommendations
about treatment during routine consultations and that
clinicians’ preferences too depended on a child’s age,
medical history and JIA subtype: “And age thing as well,
and how long they’ve had [JIA]. Because [the doctor]
tends to do it with their age doesn’t she?” (Mo1_ 11-13y).
Participants indicated that clinician treatment prefer-
ences influenced their perception of treatment efficacy
and suitability: “Probably the joint injections [would be
best] ‘cause [the doctor] said they work better ‘cause it’s
straight into the joint.” (C9_ 11-13y).
Discussion
This is the first, pre-trial qualitative feasibility study that
has involved both parents and CYP with a long term
condition. Although studies involving CYP are advo-
cated in the literature [14, 15], we are aware of only one
other early stage feasibility study that qualitatively
investigated both parents’ and CYP’s input in trial design
and conduct [14]. This explored families’ views on the
feasibility of a trial to determine optimum duration of
intravenous antibiotic therapy for children with acute
osteomyelitis or septic arthritis The current study
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recruited CYP with a long term condition, for whom
trial participation can be especially challenging [15].
While much research has focused on deficits in patients’
understanding of trials [4], we found that parents and
CYP were able to engage with the logic of the proposed
trial and identify potential flaws in its design, despite the
scenario being hypothetical [28, 29]. This suggests that
pre-trial, qualitative feasibility studies with families can
inform and optimise trial design, thereby aiming to avoid
common recruitment pitfalls [3, 4], by drawing on the
in-depth knowledge and insight families acquire in cop-
ing with a long term condition.
Contrary to previous research [30], we found that par-
ents and CYP frequently differed in their willingness to
participate in the proposed trial and in their treatment
preferences. While CYP were more permissive towards
the trial than parents, they sometimes identified
concerns that parents did not raise. This also echoes a
previous pre-trial feasibility study which found that pa-
tients with acute osteomyelitis or septic arthritis often
downplayed the impact of the illness or focused on dif-
ferent issues to their parents [14]. Previous research has
found that parents often adopt an executive or manager-
ial role in their child’s treatment and care [31], working
to identify, anticipate and meet their child’s needs [32].
Based on this previous work and findings from the
current study, we propose that CYP’s permissiveness re-
flects their reliance upon their parents to protect them
from harm and coordinate their care. CYP also trusted
clinicians with their care and, unlike parents, they did
not identify trial inconveniences (e.g. travel), which may
have also contributed to their permissive orientation.
Current guidance encourages recruiters to support fam-
ilies in sharing decisions regarding research [14]. Given
that our study and others show that CYP can offer valu-
able input to trial design [14], the viewpoints of both par-
ents and CYP are likely to be valuable in informing and
improving future paediatric clinical trials and clinical prac-
tice. The findings have helped us in developing recom-
mendations for a proposed corticosteroid induction
regimen trial (Table 3). Several of these recommendations
will be useful in developing future trials in JIA more
broadly and in avoiding common recruitment pitfalls.
While families did not deem any single treatment as
unsuitable to evaluate in the proposed trial, they
believed that treatments needed to be tailored to CYP
depending on factors such as age and JIA subtype. Previ-
ous experience of treatments also influenced such
beliefs. Our findings indicate that where families have
treatment preferences that are experience-based (e.g. tri-
als evaluating established treatments), rather than antici-
pated (e.g. trials of treatments that are new to families),
recruitment and randomisation is likely to be especially
challenging [33–36]. This is pertinent as CYP with JIA
receive treatments on repeated occasions [21]. Clinicians
recruiting to such trials will need to be prepared to
respond to questions from families who have previ-
ously experienced a particular treatment to be inef-
fective. Trialists should consider which treatment
options can be evaluated in a trial and will be toler-
ated by CYP with JIA. Some trials may need to adapt
the eligibility criteria or the treatments included to
make the trial more acceptable to families. It is also
currently unclear how decision-making about trial
participation is managed within families when treat-
ment preferences conflict; further research would be
beneficial.
Families described how clinicians had shaped their
treatment preferences via previous discussions about the
suitability of different treatments, based on factors, such
as a child’s age and the number of joints affected. Such
discussions are part of good care in routine clinical
practice, but equally, when invited to consider participa-
tion in a trial, families cannot be expected to put aside
knowledge they have previously gleaned from clinicians.
While clinician and patient treatment preferences are
often regarded as separate entities, our findings indicate
that the two can be intertwined and that the influence of
previous clinician-family discussions about treatments
needs to be considered when communicating with
families about trials. For example, clinicians will need to
respond to families’ concerns about using a treatment
that clinicians may have previously told them was un-
suitable. Indeed, clinicians and their treatment prefer-
ences can often be a considerable barrier to patient
participation in paediatric trials [37, 38]. Further qualita-
tive work exploring clinicians’ views of future JIA trials
would help to address such potential difficulties.
Similar to previous research [39], we found that trial
inconvenience, such as additional appointments, will
also likely be a recruitment barrier for parents. Trialists
will need to explore options to reduce burden, such as
completing follow-up appointments by telephone or
Skype, and arranging appointments at participants’
convenience (e.g. out of school hours).
Table 3 Summary of the recommendations for the design of a
future corticosteroid induction regimen trial in JIA
1. The views of parents and children and young people are important
in informing trial design and conduct.
2. Although families may not deem one treatment as unsuitable
overall, trialists need to establish whether all treatments are suitable
for all patients with JIA. If this is not possible, amendments to the
eligibility criteria or fewer treatments will be needed.
3. Further qualitative work should explore clinicians’ views on a future
corticosteroid induction regimen trial in JIA, to establish clinical
equipoise and support for the trial.
4. Trialists should consider methods of making a future trial more
accessible to parents and children and young people, such as
combining trial follow-up assessments with clinic appointments.
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We interviewed socio-economically diverse families
from across England with children of different ages and
varied treatment experiences. While we had interview
data from only one patient aged under 10 years, our sam-
ple did include parents of children aged 1–16 years. Add-
itionally, we interviewed families of patients who had
different sub-types of JIA and numbers of affected joints,
although we did not actively sample for these clinical
characteristics. In accessing the perspectives of CYP our
approach is consistent with current guidance on including
the voices of children in research [14]. Furthermore, the
competence of chronically ill children in communicating
about health related matters can often exceed their
chronological age [40]. We did not interview families with
a JIA diagnosis who had not yet been treated with cortico-
steroids, and we acknowledge that the views of such fam-
ilies may differ markedly from our findings. However,
interviewing families at diagnosis, but before corticoster-
oid treatment, would likely have been challenging, particu-
larly given the difficulties families experience at this time
[41], which we also reported here. This study’s sample
size is typical and appropriate for a qualitative study
given that the inferences drawn are not about preva-
lence or statistical distribution [16]. Rather, our infer-
ences concern the nature of families’ perspectives and
the value of these in informing the design of JIA tri-
als. Similar to deliberative engagement methods [42], we
used stimulus materials (see Additional file 2: Appendix
B) and discursive interviews to enable families to raise
matters of importance to them, and for us to inform fam-
ilies about trials and clarify any key misunderstandings.
Conclusion
This pre-trial qualitative feasibility study demonstrated
that families could engage in the logic of a proposed trial
in JIA and provide valuable input into trial design before
further investment of resources. We identified potential
barriers to recruitment for a corticosteroid induction
regimen trial in JIA, divergent views between parents
and CYP and areas for further exploration, including
clinician treatment preferences. This study highlights the
importance of including families in pre-trial feasibility
work to illuminate barriers to recruitment and to inform
strategies to improve informed consent and recruitment.
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